announces the further optimization of the structure and utilization of its capital via the repayment of mortgage debt and expansion of its bank line of credit – Moves that reduce interest expenses while maintaining strategic flexibility and resilience.

announce that they have signed a Memorandum Of Understanding (MOU) under which Microbix will supply its PROCEEDx™FLOQ® brand Quality Assessment Products (QAPs™) to support quality management of testing for high-risk Human Papillomavirus (HPV) infections, which cause most cases of cervical cancer.

was pleased to host Government of Ontario candidates Premier Doug Ford (Etobicoke North riding) and local MPP Deepak Anand (Mississauga-Malton riding). During their site visit on the morning of February 27 — Ontario’s Provincial Election Day — our team had great conversations about how next-generation diagnostic tests can improve health outcomes for patients while also reducing healthcare costs.

announces the issuance of stock options under its shareholder-approved stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

announces that it will be presenting to equity investors at the Whistler Capital Event conference, organized by Capital Event Management Ltd. and being hosted at the Fairmont Chateau Whistler, in Whistler, British Columbia, February 21 to 23, 2025.

reports results for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1”).

announces that it expects to file the financial statements and management disclosure and analysis for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1 2025”) prior to the start of trading on February 13, 2025

announces that it has received C$ 2.4 million in new equity capital from the partial exercise of expiring share purchase warrants.

Microbix and American Proficiency Institute (API), a groundbreaking supplier of proficiency testing (“PT”) to over 20,000 clinical laboratories, announce the start of a pilot PT program to ensure that molecular diagnostic (“MDx”) assays can detect the emerging H5N1 strain of the Influenza A virus (“H5N1 Flu”).